Evidence map›Paper›PMID 41457383›Full record

ReviewExpert reviews in molecular medicine2025

Microbiome-driven resistance in cervical cancer therapy: from mechanistic dissection to clinical translation.

Xiaoqi Wu, Dingjie Wang, Xiaodan Mao, BinHua Dong, Yue Wang

Abstract readReview
In one paragraph

Review in Expert reviews in molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiaoqi WuThe Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, P.R. China.ORCID 0009-0001-5702-0630
Dingjie Wanghttps://ror.org/050s6ns64College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, P.R. China.ORCID 0009-0002-4577-9567
Xiaodan MaoDepartment of Gynecology, Fujian Key Laboratory of Women and Children's Critical Diseases Research, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, P.R. China.
BinHua DongDepartment of Gynecology, Fujian Key Laboratory of Women and Children's Critical Diseases Research, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, P.R. China.ORCID 0000-0002-5086-0696
Yue Wanghttps://ror.org/050s6ns64Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, P.R. China.ORCID 0000-0002-5959-5294

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer remains a major global health burden. Despite standard-of-care therapies, 30-50% of locally advanced-stage patients develop treatment resistance, leading to recurrence and mortality. While tumour-intrinsic mechanisms (e.g., DNA methylation, cancer-associated fibroblasts) explain only partial resistance heterogeneity, emerging evidence identifies the microbiome as a critical modulator of therapeutic efficacy. This review synthesizes recent advances demonstrating that vaginal microbial dysbiosis, characterized by

Indexed as

Drug Resistance, NeoplasmMicrobiotaUterine Cervical NeoplasmsAnimalsDysbiosisFemaleHumansProbioticsTranslational Research, Biomedicalcervical cancergeographic variationhuman immunodeficiency virusimmunotherapylactate metabolismLactobacillusmicrobiomesynthetic biologytreatment resistance

Identifiers

PMID41457383
PMCPMC12935477

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.